Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R

[Display omitted] •Glucagon-like peptide-1 receptor (GLP-1R) was expressed in osteoclasts.•Inhibitory role of liraglutide on osteoclastogenesis.•Liraglutide inhibits osteoclastogenesis by NF-κB and MAPK pathways. Bone disorders such as osteoporosis, Paget’s disease of the bone, osteogenesis imperfec...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biomedicine & pharmacotherapy 2020-10, Vol.130, p.110523-110523, Article 110523
Hauptverfasser:	Li, Ziyi, Li, Shilun, Wang, Na, Xue, Peng, Li, Yukun
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Bone Resorption - prevention & control Cell Differentiation - drug effects Gene Knockdown Techniques GLP-1 Glucagon-Like Peptide-1 Receptor - agonists Glucagon-Like Peptide-1 Receptor - genetics Life Sciences & Biomedicine Liraglutide Liraglutide - pharmacology Macrophages - drug effects Male Medicine, Research & Experimental Mice Mice, Inbred BALB C Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors NF-kappa B - antagonists & inhibitors NFATC Transcription Factors - antagonists & inhibitors NFATC Transcription Factors - biosynthesis Osteoclast Osteoclastogenesis Osteoclasts - drug effects Osteogenesis - drug effects Pharmacology & Pharmacy RANK Ligand - antagonists & inhibitors RAW 264.7 Cells Research & Experimental Medicine Science & Technology Signal Transduction - drug effects Signalling pathway
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!